Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:35:36.050Z.
Calculation as of: 2026-10-06T15:35:36.050Z.
Quote observation: 2026-10-06T15:35:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: adca945f375d0863f0f013440b023eebfab0caffb47005764e85a23fe93f72ce
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2018-09-04.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aquestive Therapeutics, Inc.
Market Cap
$576.52M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$567.12M
EV/EBIT Ratio
N/A
TTM Avg
14.25x
3Y Avg
18.01x
5Y Avg
18.01x
Market Cap
$593.29M
EV/EBIT Ratio
N/A
TTM Avg
2.85x
3Y Avg
52.42x
5Y Avg
52.42x
Market Cap
$555.16M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $576.52M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $567.12M | N/A | 14.25x | 18.01x | 18.01x |
| OrthoPediatrics Corp. (KIDS)vs › | $588.70M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $566.03M | 2.09x | 6.25x | 15.98x | 15.98x |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $558.65M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $593.29M | N/A | 2.85x | 52.42x | 52.42x |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $555.16M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $600.42M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $556.87M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2018-09-04 | 87.80x |
| 2018-08-31 | 88.34x |
| 2018-08-30 | 84.58x |
| 2018-08-29 | 83.31x |
| 2018-08-28 | 79.32x |
| 2018-08-27 | 77.01x |
| 2018-08-24 | 78.00x |
| 2018-08-23 | 78.91x |
| 2018-08-22 | 79.09x |
| 2018-08-21 | 78.50x |
| 2018-08-20 | 79.05x |
| 2018-08-17 | 79.23x |
| 2018-08-16 | 79.68x |
| 2018-08-15 | 81.31x |
| 2018-08-14 | 81.63x |
| 2018-08-13 | 80.00x |
| 2018-08-10 | 77.78x |
| 2018-08-09 | 74.97x |
| 2018-08-08 | 74.97x |
| 2018-08-07 | 74.74x |
| 2018-08-06 | 74.69x |
| 2018-08-03 | 74.74x |
| 2018-08-02 | 74.79x |
| 2018-08-01 | 75.15x |
| 2018-07-31 | 74.88x |
| 2018-07-30 | 74.97x |
| 2018-07-27 | 75.51x |
| 2018-07-26 | 78.55x |
| 2018-07-25 | 79.46x |
